Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 3/20 | 0.55 |
| ▸ | USP19 | O94966 | 2/20 | 0.55 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.55 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.50 |
| ▸ | USP8 | P40818 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | OTUB1 | Q96FW1 | 1/20 | 0.48 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129367 | 0.78 | USP1 (0.50) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL7818903 | 0.74 | USP1 (0.60) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL24199862 | 0.73 | USP1 (0.45) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL19865967 | 0.73 | USP1 (0.45) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL16888426 | 0.72 | CYP1A2 (0.44) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL2292267 | 0.72 | ELANE (0.37) | ELANECYP1A2CYP3A4CYP2C19NR4A2 | |
| SCHEMBL29629183 | 0.71 | USP1 (1.00) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL7808226 | 0.71 | USP1 (1.00) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL19198308 | 0.71 | USP1 (0.57) | USP1USP19WDR48UCHL3USP8 | |
| SCHEMBL29629184 | 0.71 | USP1 (1.00) | USP1USP19WDR48UCHL3USP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306063-B2 | Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-04-19 | — | — | US | disclosed |
| EP-3497083-B1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2022-01-19 | — | — | EP | disclosed |
| EP-3497083-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-06 | — | — | US | disclosed |
| WO-2018029137-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-02-15 | — | — | WO | disclosed |
| EP-3281940-A1 | HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE | COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2018-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306063-B2 | Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease | NEDD8, USP8, USP18 | USP1 5/4885USP19 35/4885WDR48 245/4885 |
| US-20190169136-A1 | Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease | NEDD8, USP8, USP18 | USP1 5/4885USP19 35/4885WDR48 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.